1. Home
  2. QNRX vs BGLC Comparison

QNRX vs BGLC Comparison

Compare QNRX & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

HOLD

Current Price

$12.25

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Logo BioNexus Gene Lab Corp Common stock

BGLC

BioNexus Gene Lab Corp Common stock

HOLD

Current Price

$4.24

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNRX
BGLC
Founded
2018
2017
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
10.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
QNRX
BGLC
Price
$12.25
$4.24
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
154.3K
311.3K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$9,465,006.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.21
52 Week Low
$5.01
$2.01
52 Week High
$41.80
$15.60

Technical Indicators

Market Signals
Indicator
QNRX
BGLC
Relative Strength Index (RSI) 42.32 41.85
Support Level $11.48 $4.00
Resistance Level $15.45 $4.31
Average True Range (ATR) 2.60 0.26
MACD -1.05 0.00
Stochastic Oscillator 11.54 33.47

Price Performance

Historical Comparison
QNRX
BGLC

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: